Loading...

MaxCyte, Inc.

MXCT.LLSE
HealthcareMedical - Devices
$177.00
$-3.00(-1.67%)

MaxCyte, Inc. (MXCT.L) Stock Overview

Explore MaxCyte, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-6.44%
6.44%
Profit Growth
$-0.39
8.26%
EPS Growth
$-0.39
5.41%
Operating Margin
-132.54%
6.00%
ROE
-18.94%
8.26%
Dividend Yield
0.00%
Analyst Recommendations data is not available for MXCT.LAnalyst Recommendations details for MXCT.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

CEO

Mr. Maher Masoud

Employees

114

Headquarters

9713 Key West Avenue, Rockville, MD

Founded

2016

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.